These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28054141)

  • 1. Indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in elderly patients with peritoneal malignancy.
    Kitai T; Yamanaka K; Miyauchi Y; Kawashima M
    Int J Clin Oncol; 2017 Jun; 22(3):519-525. PubMed ID: 28054141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients: Complete Cytoreduction Is Feasible and Crucial for Improved Survival Despite High Carcinomatosis Index.
    Naffouje SA; Salti GI
    Anticancer Res; 2018 Jan; 38(1):441-448. PubMed ID: 29277807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis in the Elderly: A Case-Controlled, Multicenter Study.
    Alyami M; Lundberg P; Kepenekian V; Goéré D; Bereder JM; Msika S; Lorimier G; Quenet F; Ferron G; Thibaudeau E; Abboud K; Lo Dico R; Delroeux D; Brigand C; Arvieux C; Marchal F; Tuech JJ; Guilloit JM; Guyon F; Peyrat P; Pezet D; Ortega-Deballon P; Zinzindohoue F; de Chaisemartin C; Kianmanesh R; Glehen O; Passot G;
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):737-745. PubMed ID: 27600619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.
    Martin AS; Abbott DE; Hanseman D; Sussman JE; Kenkel A; Greiwe P; Saeed N; Ahmad SH; Sussman JJ; Ahmad SA
    Ann Surg Oncol; 2016 Jun; 23(6):1941-7. PubMed ID: 26842489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
    van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
    Bhagwandin SB; Naffouje S; Salti G
    J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritoneal Involvement Is More Common Than Nodal Involvement in Patients With High-Grade Appendix Tumors Who Are Undergoing Prophylactic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Mehta A; Mittal R; Chandrakumaran K; Carr N; Dayal S; Mohamed F; Moran B; Cecil T
    Dis Colon Rectum; 2017 Nov; 60(11):1155-1161. PubMed ID: 28991079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center.
    Wu HT; Peng KW; Ji ZH; Sun JH; Zhang Q; Yang XJ; Huang CQ; Li Y
    Eur J Surg Oncol; 2016 Jul; 42(7):1024-34. PubMed ID: 27179924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
    Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
    World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Dagbert F; Thievenaz R; Decullier E; Bakrin N; Cotte E; Rousset P; Vaudoyer D; Passot G; Glehen O
    Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.
    Downs-Canner S; Ding Y; Magge DR; Jones H; Ramalingam L; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2015 May; 22(5):1651-7. PubMed ID: 25348781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morbidity and mortality of elderly patients following cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Wong EYT; Tan GHC; Chia CSL; Kumar M; Soo KC; Teo MCC
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e193-e202. PubMed ID: 28695617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreduction with hyperthermic intraperitoneal chemotherapy: an appraisal of outcomes and cost at a newly established peritoneal malignancy program.
    Hinkle NM; MacDonald J; Sharpe JP; Dickson P; Deneve J; Munene G
    Am J Surg; 2016 Sep; 212(3):413-8. PubMed ID: 27086201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.
    Canda AE; Arslan C; Terzi C; Sokmen S; Yavuzsen T; Ozkardesler S; Unlu M; Obuz F; Fuzun M
    World J Surg Oncol; 2018 Mar; 16(1):70. PubMed ID: 29587771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies.
    Passot G; Bakrin N; Isaac S; Decullier E; Gilly FN; Glehen O; Cotte E
    Eur J Surg Oncol; 2014 Aug; 40(8):957-62. PubMed ID: 24209429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.